


+ Evidence in focus

Publication summary: Lavery LA, et al. *Int Wound J* (2014)*

Smith+Nephew

Significantly more patients with chronic diabetic foot ulcers (DFUs) achieved complete wound closure in a shorter time with GRAFIX[◊] Cryopreserved Placental Membrane than with standard care

+ Plus points




Overview

- Prospective, multicenter, randomized, single-blinded study
- Patients with DFUs (duration 4–52 weeks) received once weekly GRAFIX Membrane (n=50) or standard care of off-loading and non-adherent dressings (n=47) for up to 84 days
- All wounds were appropriately cleaned and surgically debrided at each weekly visit
- Patients receiving standard care whose wounds had not closed by the end of the blinded treatment phase were able to receive GRAFIX Membrane in an open-label treatment phase (84 days)

Results

- GRAFIX Membrane use significantly increased the number of DFUs that achieved complete closure compared with standard care (p=0.0001; Figure)
 - DFUs remained closed at 12-week follow-up in 82.1% of patients with GRAFIX Membrane and 70.0% of patients with standard care
- Median time to complete wound closure was significantly faster with GRAFIX Membrane versus standard care (42.0 vs 69.5 days; p=0.019)
- Complete wound closure was achieved with 50% fewer study visits with GRAFIX Membrane than with standard care (6 vs 12 visits; p<0.001)
- For patients who had failed to heal with standard care alone and added GRAFIX Membrane (n=26), the probability of DFU closure was 67.8% with a mean closure time of 42 days



Conclusions

Significantly more patients with chronic DFUs achieved complete wound closure in a shorter time using GRAFIX Membrane compared with standard care.

Citation

*Lavery LA, Fulmer J, Shebetka KA, et al. The efficacy and safety of GRAFIX[◊] for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. *Int Wound J*. 2014;11(5):554–560.

Available from: [International Wound Journal](#)

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Study sponsored by Osiris Therapeutics Inc, which is now a wholly owned direct subsidiary of Smith & Nephew Consolidated, Inc. **Advanced Wound Management.** Smith & Nephew, Inc. Fort Worth, TX 76109 USA | GRAFIX Customer Care Center: T 888-674-9551 F 443-283-4419 | ◊Osiris, GRAFIX, GRAFIXPL, GRAFIX PRIME, GRAFIX CORE, GRAFIX XC, and GRAFIXPL PRIME are trademarks of Osiris Therapeutics, Inc., a wholly owned direct subsidiary of Smith & Nephew Consolidated, Inc. | ©2022 Smith & Nephew, Inc. | GRCE45-34990-1022 www.smith-nephew.com www.osiris.com

www.smith-nephew.com/education